MedTech News
.................... by Andrew Celentano
Increasing protective protein suppresses Parkinson’s-linked buildup, more than doubling lifespan in mouse model
Parkinson’s disease is the second most common neurodegenerative disease. Over the last 30 years, studies have shown that a protein called alpha-synuclein abnormally aggregates in people with Parkinson’s disease, becoming toxic to neurons in a region of the brain that controls movement. This leads to tremor, rigidity and slowness of movement.
T-cell research reveals paths to better vaccines for COVID-19 and beyond
Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and the other might end up on a ventilator. But why?
Gut microbes help set the body’s inflammatory response to vaccination
Vaccination is one of the most important tools for preventing infectious diseases and protecting public health. However, immune responses after vaccination vary dramatically from person to person: If you give many people the exact same vaccine, some will experience side effects such as fever and flulike symptoms while others feel fine.
Okami Medical Receives FDA Expanded Indication for LOBO Vascular Occluder in Peripheral Veins
Okami Medical has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for its LOBO Vascular Occlusion System.
Wearable tech gives women ‘proof their pain is real’
Women struggling to secure answers for suspected endometriosis and PMOS could be given stronger evidence of their symptoms through wearable technology shaped by its founder’s own lived experience. WombWise, founded by Edinburgh Napier University graduate Emily Youngs, has been crowned winner of the Create Change Challenge at the Converge Awards.
Viome Launches CancerDetect® Pancreatic, Built For Early Pancreatic Cancer Detection
BELLEVUE, Wash., Oct. 8, 2026 /PRNewswire/ — Viome PRO, the clinical division of Viome Life Sciences, today launched CancerDetect® Pancreatic, a blood test that looks for pancreatic ductal adenocarcinoma by measuring the enzyme activity associated with the disease. In Viome’s blinded validation, the test detected 86 percent of stage I and II cancers with 90 percent specificity, a performance aimed squarely at the early stages where treatment can still change the outcome. The test is ordered by a physician, drawn as a routine venous sample, and processed in Viome’s CLIA-certified laboratory.
Sonorous wins FDA IDE for pulsatile tinnitus stent pivotal trial initiation
Sonorous’ FDA IDE approval follows its BosSTENT’s receipt of FDA breakthrough device designation in February 2026.
Argus Cognitive’s paediatric autism diagnostic secures FDA clearance
Argus’s Neurora tool is intended to complement clinicians’ professional judgement rather than serve as a standalone diagnostic for autism.